Cambium Oncology Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1.05M
- Investors
-
5
Cambium Oncology General Information
Description
Developer of immunotherapeutic drugs designed to treat rare cancers by targeting the vasoactive intestinal peptide neuro-immune checkpoint pathway. The company's platform develops therapeutic candidates that inhibit vasoactive intestinal peptide signaling and modulate immune cell activity, enabling oncology clinicians and cancer treatment centers to address tumor immune evasion and expand treatment options for patients with limited responses to existing immunotherapies.
Contact Information
Website
www.cambiumoncology.comCorporate Office
- 1750 Haygood Drive North East
- Atlanta, GA
- United States
Corporate Office
- 1750 Haygood Drive North East
- Atlanta, GA
- United States
Cambium Oncology Timeline
Cambium Oncology Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Grant | 22-Jul-2026 | $1.05M | Completed | Pre-Clinical Trials | ||
| 4. Later Stage VC | 13-Jan-2025 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 13-Jan-2025 | Completed | Pre-Clinical Trials | |||
| 2. Accelerator/Incubator | 01-Sep-2023 | Completed | Pre-Clinical Trials | |||
| 1. Early Stage VC | 01-Jan-2021 | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Cambium Oncology Comparisons
Industry
Financing
Details
Cambium Oncology Competitors (4)
One of Cambium Oncology’s 4 competitors is Amgen, a Formerly PE-Backed company based in Thousand Oaks, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Sanofi | Corporation | Gentilly, France | ||||
| Johnson & Johnson | Corporation | New Brunswick, NJ |
Cambium Oncology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cambium Oncology Patents
Cambium Oncology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025217056-A2 | Vasoactive intestinal polypeptide (vip) receptor antagonists fc fusions and methods of use | Pending | 08-Apr-2024 | ||
| AU-2022279136-A1 | Vasoactive intestinal peptide (vip) receptor antagonists | Pending | 17-May-2021 | ||
| AU-2022279136-A9 | Vasoactive intestinal peptide (vip) receptor antagonists | Pending | 17-May-2021 | ||
| CA-3216694-A1 | Vasoactive intestinal peptide (vip) receptor antagonists | Pending | 17-May-2021 | ||
| EP-4341282-A1 | Vasoactive intestinal peptide (vip) receptor antagonists | Pending | 17-May-2021 | C07K14/72 |
Cambium Oncology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cambium Oncology Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Cancer Institute | Government | Minority | ||
| National Institutes of Health | Government | |||
| Orient Europharma Company | Corporation | Minority | ||
| Biolocity | Accelerator/Incubator | Minority | ||
| Georgia Research Alliance | Not-For-Profit Venture Capital | Minority |
Cambium Oncology FAQs
-
When was Cambium Oncology founded?
Cambium Oncology was founded in 2018.
-
Where is Cambium Oncology headquartered?
Cambium Oncology is headquartered in Atlanta, GA.
-
What is the size of Cambium Oncology?
Cambium Oncology has 4 total employees.
-
What industry is Cambium Oncology in?
Cambium Oncology’s primary industry is Drug Discovery.
-
Is Cambium Oncology a private or public company?
Cambium Oncology is a Private company.
-
What is Cambium Oncology’s current revenue?
The current revenue for Cambium Oncology is .
-
How much funding has Cambium Oncology raised over time?
Cambium Oncology has raised $5M.
-
Who are Cambium Oncology’s investors?
National Cancer Institute, National Institutes of Health, Orient Europharma Company, Biolocity, and Georgia Research Alliance have invested in Cambium Oncology.
-
Who are Cambium Oncology’s competitors?
Amgen, Bristol-Myers Squibb, Sanofi, and Johnson & Johnson are competitors of Cambium Oncology.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
